In collaboration with the Paul-Ehrlich-Institute and the German Center for Infection Research, the company is now using its immuno-oncology technology to develop a measles-vectored COVID-19 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback